题名 |
簡介阿滋海默症藥物與注意事項 |
并列篇名 |
The Introduction and Caution of Medication for Alzheimer Disease |
DOI |
10.6647/CN.202209_29(3).0007 |
作者 |
徐麗珍(Li-Jen Hsu) |
关键词 |
阿滋海默症 ; Donepezil ; Rivastigmine ; Galantamine ; Memantine ; Alzheimer disease ; Donepezil ; Rivastigmine ; Galantamine ; Memantine |
期刊名称 |
彰化護理 |
卷期/出版年月 |
29卷3期(2022 / 09 / 01) |
页次 |
37 - 43 |
内容语文 |
繁體中文 |
中文摘要 |
阿滋海默症占失智症病人族群大宗,其治療藥物雖然無法反轉或根治疾病,但可改善症狀、延緩認知功能惡化速度,對病人、照護者實有助益。但臨床用藥時須注意少數病人可能無法耐受藥物副作用、罹患某些疾病的患者是否有因藥物導致疾病復發或惡化的異常情況,應採取適當的處理措施以維護阿滋海默症病人的用藥安全。 |
英文摘要 |
Alzheimer disease accounts for the majority of the dementia population. Although Alzheimer disease cannot be reversed or cured by medication, these drugs may improve symptoms and delay the deterioration of cognitive function, which is really helpful to patients and caregivers. However, when taking these medication, it is necessary to pay attention to the fact that few patients may not tolerate adverse drug reactions, and whether patients suffering from certain diseases have abnormal conditions of recurrence or deterioration caused by these drugs. An appropriate approach should be taken to stand up for the medication safety of patients with Alzheimer disease. |
主题分类 |
醫藥衛生 >
預防保健與衛生學 醫藥衛生 > 社會醫學 |
参考文献 |
|